Panosialin C
* Please be kindly noted products are not for therapeutic use. We do not sell to patients.
| Category | Enzyme inhibitors |
| Catalog number | BBF-03748 |
| CAS | |
| Molecular Weight | 494.66 |
| Molecular Formula | C22H38O8S2 |
Online Inquiry
Description
It is produced by the strain of Str. sp OH-5186. It can inhibit α,β-glucosidase and mannose glycosidase. It does not inhibit the influenza virus, but it has weak anti-microbial effect.
Specification
| Synonyms | 5-(14-Methylpentadecyl)resorcinol 1,3-bissulfuric acid; Panosialin III |
| IUPAC Name | [3-(14-methylpentadecyl)-5-sulfooxyphenyl] hydrogen sulfate |
| Canonical SMILES | CC(C)CCCCCCCCCCCCCC1=CC(=CC(=C1)OS(=O)(=O)O)OS(=O)(=O)O |
| InChI | InChI=1S/C22H38O8S2/c1-19(2)14-12-10-8-6-4-3-5-7-9-11-13-15-20-16-21(29-31(23,24)25)18-22(17-20)30-32(26,27)28/h16-19H,3-15H2,1-2H3,(H,23,24,25)(H,26,27,28) |
| InChI Key | UXYUMXXZKYABDN-UHFFFAOYSA-N |
Properties
| Appearance | White Powder |
| Density | 1.2±0.1 g/cm3 |
| Solubility | Soluble in Methanol |
Reference Reading
1. New World cutaneous leishmaniasis: current challenges in diagnosis and parenteral treatment
Danny Zaghi, Claire Panosian, Miguel A Gutierrez, Aric Gregson, Emma Taylor, Maria Teresa Ochoa J Am Acad Dermatol. 2011 Mar;64(3):587-92. doi: 10.1016/j.jaad.2009.08.045. Epub 2010 May 21.
Many physicians in the United States and other nonendemic countries lack familiarity with New World cutaneous leishmaniasis (CL) and fail to include it in their differential diagnosis when seeing patients with suggestive lesions and recent high-risk travel. Moreover, even when the diagnosis of New World CL is considered and confirmed, physicians in the United States still face obstacles in obtaining appropriate treatment. In this report, we present 3 cases of New World CL that were either initially misdiagnosed or faced significant delays in therapy. We also discuss the optimal approach by which to confirm New World CL and to collaborate with professional colleagues at the Centers for Disease Control and Prevention in treating individual patients. In particular, when pentavalent antimonial treatment is needed for treatment, physicians must obtain appropriate diagnostic studies, communicate with experts at the Centers for Disease Control and Prevention, complete necessary paperwork, and obtain approval from their local institutional review board to administer it.
2. Human antiprotozoal therapy: past, present, and future
M Khaw, C B Panosian Clin Microbiol Rev. 1995 Jul;8(3):427-39. doi: 10.1128/CMR.8.3.427.
Human protozoal infections are ubiquitous and occur worldwide. In many cases, antiprotozoal agents currently in use predate the modern antibiotic era. Despite the relative lag in development of new antiprotozoal agents, the 1990s have witnessed an increasing level of interest in these infections, inspired by international travel and immigration, a growing awareness of antiprotozoal drug resistance, and the significance of acute and recrudescent protozoal infections in immunosuppressed hosts. This review summarizes for nonclinician readers the past, present, and future therapies for common human protozoal infections, as well as pharmacologic mechanisms of action and resistance and common toxicities associated with these agents.
3. Imported echinococcosis in southern California
S M Donovan, N Mickiewicz, R D Meyer, C B Panosian Am J Trop Med Hyg. 1995 Dec;53(6):668-71. doi: 10.4269/ajtmh.1995.53.668.
A retrospective chart review conducted at two teaching hospitals in Los Angeles County identified 28 patients with infection due to Echinococcus granulosus diagnosed by positive echinococcal serology and/or tissue biopsy between January 1981 and December 1990. Of these patients, 25 (89%) were foreign born and 19 (68%) were immigrants from the Middle East or central Asia. Only 12 of 22 immigrants questioned about epidemiologic risk factors described a history of rural residence or direct exposure to dogs in their native country. Single cysts of liver, lung, and soft tissue were present in six of 28 patients; multiple cysts in the 22 remaining patients were exclusively hepatic in 13 patients, exclusively pulmonary in two patients, and involved mixed sites including liver, lung, abdomen, central nervous system, and bone in seven patients. Natives of middle eastern countries currently constitute a major risk group for imported infection due to E. granulosus in the United States. Since their epidemiologic risk factors may be absent and clinical presentations varied, a high index of suspicion for echinococcosis is warranted in this population based solely on the presence of a cystic mass in liver, lung, or another organ site.
Recommended Products
| BBF-01825 | Loganin | Inquiry |
| BBF-00764 | Cerebroside C | Inquiry |
| BBF-03753 | Baicalin | Inquiry |
| BBF-01829 | Deoxynojirimycin | Inquiry |
| BBF-00677 | 3-Amino-3-deoxy-D-glucose | Inquiry |
| BBF-02642 | Lactonamycin | Inquiry |
Bio Calculators
* Our calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
It is commonly abbreviated as: C1V1 = C2V2
* Total Molecular Weight:
g/mol
Tip: Chemical formula is case sensitive. C22H30N4O √ c22h30n40 ╳
